These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 2193992)

  • 21. Pathophysiology of diabetic nephropathy.
    Sego S
    Nephrol Nurs J; 2007; 34(6):631-3. PubMed ID: 18203571
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Progression of chronic renal insufficiency and its prevention using angiotensin converting enzyme inhibitors and angiotensin antagonists].
    Tesar V
    Vnitr Lek; 2003 May; 49(5):365-9. PubMed ID: 12908169
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Hyperfiltration].
    Kaida Y; Ueda S; Okuda S
    Nihon Rinsho; 2010 Nov; 68 Suppl 9():385-9. PubMed ID: 21667491
    [No Abstract]   [Full Text] [Related]  

  • 24. [Prediction, screening and treatment of renal complications of diabetes].
    Marre M; Larger E
    Rev Prat; 2001 Oct; 51(16):1769-75. PubMed ID: 11795120
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Progressive renal insufficiency: the role of angiotensin converting enzyme inhibitors.
    Savage S; Schrier RW
    Adv Intern Med; 1992; 37():85-101. PubMed ID: 1558007
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ACE inhibitor slows onset of renal disease in diabetics by 50%.
    Lefton CK
    Nephrol News Issues; 1993 Dec; 7(12):8, 11. PubMed ID: 8264813
    [No Abstract]   [Full Text] [Related]  

  • 27. Kinins are involved in the antiproteinuric effect of angiotensin-converting enzyme inhibition in experimental diabetic nephropathy.
    Tschöpe C; Seidl U; Reinecke A; Riester U; Graf K; Schultheiss HP; Hilgenfeldt U; Unger T
    Int Immunopharmacol; 2003 Mar; 3(3):335-44. PubMed ID: 12639811
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Complete remission of diabetic nephropathy in a type 1 diabetic patient with near-nephrotic range proteinuria and reduced renal function.
    Haraguchi K; Hara S; Ubara Y; Tanaka S; Nukui I; Shimura H; Ohashi K; Kobayashi T
    Diabetes Res Clin Pract; 2009 Mar; 83(3):295-9. PubMed ID: 19162360
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Dialysis in diabetic nephropathy].
    Katsumata Y; Akiba T
    Nihon Rinsho; 2005 Jun; 63 Suppl 6():424-9. PubMed ID: 15999746
    [No Abstract]   [Full Text] [Related]  

  • 30. The renoprotective action of angiotensin-converting enzyme inhibitors in diabetes.
    Ruggenenti P; Remuzzi G
    Exp Nephrol; 1996; 4 Suppl 1():53-60. PubMed ID: 9001898
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent progress in the management of end-stage diabetic nephropathy.
    Goetz FC
    Clin Endocrinol Metab; 1982 Jul; 11(2):579-90. PubMed ID: 6754167
    [No Abstract]   [Full Text] [Related]  

  • 32. Clinical trials in progression of chronic renal failure.
    Striker GE; Klahr S
    Adv Intern Med; 1997; 42():555-95. PubMed ID: 9048130
    [No Abstract]   [Full Text] [Related]  

  • 33. Effect of strict glycemic control on renal hemodynamic response to amino acids and renal enlargement in insulin-dependent diabetes mellitus.
    Tuttle KR; Bruton JL; Perusek MC; Lancaster JL; Kopp DT; DeFronzo RA
    N Engl J Med; 1991 Jun; 324(23):1626-32. PubMed ID: 2030719
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diabetic nephropathy in the tropics.
    Ramachandran S; Rajapakse CN; Yoganathan M
    J Indian Med Assoc; 1973 Jul; 61(1):28-32. PubMed ID: 4759067
    [No Abstract]   [Full Text] [Related]  

  • 35. Peroxisome proliferator-activated receptor [gamma] agonist provides superior renal protection versus angiotensin-converting enzyme inhibition in a rat model of type 2 diabetes with obesity.
    Baylis C; Atzpodien EA; Freshour G; Engels K
    J Pharmacol Exp Ther; 2003 Dec; 307(3):854-60. PubMed ID: 14560039
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Functional role of tubuloglomerular feedback control of glomerular filtration.
    Wright FS; Okusa MD
    Adv Nephrol Necker Hosp; 1990; 19():119-33. PubMed ID: 2105576
    [No Abstract]   [Full Text] [Related]  

  • 37. A perspective on converting enzyme inhibitors and calcium channel antagonists in diabetic renal disease.
    Valentino VA; Wilson MD; Weart W; Bakris GL
    Arch Intern Med; 1991 Dec; 151(12):2367-72. PubMed ID: 1746992
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Risk for hyperkalemia during long-term treatment with angiotensin-converting enzyme inhibitors in insulin-dependent type 2 diabetics in relation to the glomerular filtration rate].
    Raml A; Schmekal B; Grafinger P; Biesenbach G
    Dtsch Med Wochenschr; 2001 Nov; 126(47):1327-30. PubMed ID: 11719857
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Diagnosis of and therapy for patients with diabetic nephropathy].
    Doi T
    Nihon Naika Gakkai Zasshi; 2004 Mar; 93(3):569-73. PubMed ID: 15052822
    [No Abstract]   [Full Text] [Related]  

  • 40. Pathogenesis of diabetic glomerulopathy: hemodynamic considerations.
    Hostetter TH
    Semin Nephrol; 1990 May; 10(3):219-27. PubMed ID: 2190279
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.